• Revenues up 74% to $660,000 for the half-year
• Loss reduced by 7% to $2.195 million
• Expanded sales funnel and commercial partnerships across clean energy and life sciences

The half-year report of AnteoTech Ltd for the period ended 31 December 2024 shows the company has made progress in the commercialization of its proprietary applied materials technology. Revenues during the Financial Half-Year exceeded those for the 12 months of the previous financial year, up 74% to $660,000. The company's loss was reduced by 7% to $2.195 million. AnteoTech's strategy of developing a marketing-led and customer-centric approach to growth is gaining traction, with the company expanding its sales funnel and commercial partnerships across the clean energy and life sciences sectors. In the clean energy technology division, the company is targeting opportunities across the battery value chain and has entered into multiple engagements, including Materials Transfer Agreements, with separator material companies, specialty chemical companies and carbon nanotube manufacturers. In the life sciences business, the company entered into a five-year commercial supply agreement with the Serum Institute of India, the world's largest vaccine manufacturer, and is working with point-of-care manufacturer Vidcare Innovations. The company also strengthened its balance sheet, raising $4.31 million through a share placement and entitlement offer.

The company is focusing on progressing sales in India, which has been identified as a key growth market, and is working to accelerate programs with opportunities across the battery value chain that are most likely to deliver commercial outcomes in the near term. The company is also exploring additional opportunities in the rapidly growing Indian healthcare market.